INKT MiNK Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INKT

Price (delayed)

$0.98

Market cap

$34.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$30.64M

Highlights
INKT's EPS is up by 22% year-on-year and by 11% since the previous quarter
MiNK Therapeutics's net income has increased by 20% YoY and by 9% QoQ
MiNK Therapeutics's quick ratio has plunged by 81% YoY and by 52% from the previous quarter
MiNK Therapeutics's equity has decreased by 33% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of INKT
Market
Shares outstanding
34.7M
Market cap
$34.01M
Enterprise value
$30.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$22.46M
EBITDA
-$22.25M
Free cash flow
-$15.84M
Per share
EPS
-$0.65
Free cash flow per share
-$0.46
Book value per share
-$0.52
Revenue per share
$0
TBVPS
$0.13
Balance sheet
Total assets
$4.55M
Total liabilities
$22.61M
Debt
$0
Equity
-$18.06M
Working capital
-$7.8M
Liquidity
Debt to equity
0
Current ratio
0.32
Quick ratio
0.3
Net debt/EBITDA
0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-220.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INKT stock price

How has the MiNK Therapeutics stock price performed over time
Intraday
1.03%
1 week
5.38%
1 month
1.58%
1 year
-16.24%
YTD
-8.41%
QTD
7.89%

Financial performance

How have MiNK Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.92M
Net income
-$22.46M
Gross margin
N/A
Net margin
N/A
INKT's operating income is up by 26% YoY and by 9% QoQ
MiNK Therapeutics's net income has increased by 20% YoY and by 9% QoQ

Growth

What is MiNK Therapeutics's growth rate over time

Valuation

What is MiNK Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INKT's EPS is up by 22% year-on-year and by 11% since the previous quarter
MiNK Therapeutics's equity has decreased by 33% from the previous quarter

Efficiency

How efficient is MiNK Therapeutics business performance
MiNK Therapeutics's ROA has plunged by 125% YoY and by 28% from the previous quarter

Dividends

What is INKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INKT.

Financial health

How did MiNK Therapeutics financials performed over time
The total assets is 80% lower than the total liabilities
MiNK Therapeutics's quick ratio has plunged by 81% YoY and by 52% from the previous quarter
INKT's current ratio has dropped by 80% year-on-year and by 48% since the previous quarter
The debt is 100% more than the equity
MiNK Therapeutics's equity has decreased by 33% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.